Publications by authors named "S Kilickap"
BACKGROUND This retrospective study from a single center included 289 patients diagnosed with advanced non-small cell lung cancer (NSCLC) between 2010 to 2017 and aimed to evaluate the effects of body mass index (BMI) on overall survival. MATERIAL AND METHODS This retrospective study involved 289 patients diagnosed with metastatic-stage NSCLC at a single institution between January 2010 and December 2017. Patients were categorized into 2 groups based on their BMI at diagnosis: those with a BMI <25 kg/m² and those with a BMI ≥25 kg/m².
View Article and Find Full Text PDFArticle Synopsis
- The study examined the impact of immunotherapy in renal patients with urothelial carcinoma, categorizing them based on their glomerular filtration rate (GFR).
- Results showed that patients with normal GFR had a higher overall response rate and longer duration of response compared to those with low and very low GFRs.
- The findings indicated that while normal GFR patients had better outcomes, immunotherapy still proved effective for patients with impaired renal function who lacked other treatment options.
Article Synopsis
- The study investigates the response to first-line PD-1 inhibitors, pembrolizumab and cemiplimab, in patients with metastatic NSCLC, focusing on those with different PD-L1 tumor proportion scores (TPS).
- It compares survival rates between patients with a PD-L1 TPS of 90% or higher and those with a score of 50% to 89%, finding significantly better outcomes for the higher TPS group in both treatment cohorts.
- Genomic profiling identified specific mutations more prevalent in lower PD-L1 expression tumors, highlighting key biological differences that may influence treatment responses.
BACKGROUND The advanced lung cancer inflammation index (ALI) is regarded as a potential indicator of systemic inflammation. This retrospective study aimed to evaluate the prognostic role of the ALI in 96 patients with advanced small cell lung cancer (SCLC). MATERIAL AND METHODS This retrospective study included 96 patients who were diagnosed with extensive stage SCLC in a single institution between 2016 and 2022.
View Article and Find Full Text PDFArticle Synopsis
- This study assessed whether the RECIST criteria for objective response rates (ORR) could predict long-term overall survival (OS) in metastatic urothelial carcinoma patients undergoing immune checkpoint inhibitor (ICI) therapy.
- The analysis revealed that 47% of patients had disease progression within the first 3 months, with complete response (CR) seen in 10%, partial response (PR) in 23%, and stable disease (SD) in 20% of cases.
- Key findings showed that 5-year OS rates significantly favored CR (73%) over PR (23%), and certain factors like liver metastases and response type were critical indicators of OS, highlighting the relevance of ORR as a potential surrogate endpoint.